Effect of HCV and HIV on mortality among injecting drug users

HIV Treatment Bulletin - Vol. 8, No. 6/7, June-July 2007

Jason Grebely and co-workers from CHASE (a cohort study of Vancouver inner city residents recruited from January 2003 to June 2004) presented mortality data from this cohort.

The investigators found, of 2069 participants identified, 721 were both HCV and HIV-negative (HCV–/HIV–), 962 were HCV-positive and HIV-negative (HCV+/HIV–), 33 were HCV negative and HIV-positive (HCV–/HIV+), and 353 were HCV and HIV-positive (HCV+/HIV+).

Among the 82 reported deaths, they found common causes of death were HIV (25.6%) and unnatural causes (19.5%). The natural cause mortality rate was 15.5 deaths/1000 person-years overall (n = 66), 9.6 deaths/1000 person-years for HCV–/HIV– (n = 15), 11.0 deaths/1000 person-years for HCV+/HIV– (n = 28), 30.4 deaths/1000 person-years for HCV–/HIV+ (n = 2), and 37.8 deaths/1000 person-years for HCV+/HIV+ subjects (n = 37).

For HCV–/HIV+ and HCV+/HIV– subjects, mortality attributed to HIV and HCV was 15.2 and 2.0 deaths/1000 person-years. In HCV+/HIV+ subjects, mortality attributed to HIV and HCV were 25.6 and 1.3 deaths/1000 person-years. Overall, natural cause mortality was associated with HIV infection (adjusted HR 5.3, 3.0 to 9.7, p<0.001), age (HR 1.8/10-year increase, 1.3 to 2.4, p <0.001) and aboriginal ethnicity (HR 1.7, 0.96 to 3.0, p = 0.07), and not associated with HCV infection (HR 1.0, 0.50 to 2.0, p = 0.99).

The investigators concluded that mortality rates in IDUs were high in this analysis, and HIV infection gave a 5-fold increase in risk of mortality. They noted that due to the timing of the HCV epidemic in this population, there has been little impact of HCV on mortality to date. “They wrote “Without programmes to treat HCV in this group, we expect a significant increase in mortality attributable to HCV infection.”

Ref: Grebely J, Raffa J, Conway B et al. Effect of hepatitis C virus and HIV infections on mortality among illicit drug users. 14th CROI, 2007, Los Angeles. Poster Abstract 922.

2007-06-10
IB070806-17

©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.